Remembering Dr. Craig Leonardi
The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.
IPC Councilor José-Manuel Carrascosa Carrillo, MD, PhD, on the BeNeBio trial and whether dose reduction fits an era focused on disease modification.
What happened in psoriasis at the 2026 EADV Congress? IPC shares highlights from its symposium on personalized medicine, as well as psoriasis sessions and late-breaking research from Vienna.
World Psoriasis Day, observed each year on October 29, was launched by the International Federation of Psoriasis Associations (IFPA) in 2004 to give a voice to the more than 125 million people worldwide living with psoriasis and psoriatic arthritis. To mark this year’s observance, IPC joined the Latin American Society of Psoriasis and Dermoimmunology (SOLAPSO) and the Skin Inflammation and Psoriasis International Network (SPIN) to create a video series around the theme “Look Beyond My Skin,” featuring voices from all three organizations. Missed the videos on social media? Watch the full series on the IPC YouTube channel.
Take Two with IPC gives a longer presentation a second life in two minutes. Each video takes an expert talk IPC has already published (a Take Ten recording or a symposium presentation) and condenses the clinical substance. The series launched this month alongside the World Psoriasis Day campaign with four videos on pediatric psoriasis: Psoriasis Look-Alikes and Anti-TNF-α Induced Skin Eruptions with IPC Board Member Amy Paller, MS, MD; Conventional Therapies with IPC Councilor Mona El-Kalioby, MBBCh, MSc, MD; and Phototherapy in Pediatric Psoriasis with Fernando Valenzuela, MD. New Take Two videos will be featured each month, drawn from the Take Ten with IPC library and recordings from IPC symposia, with a link to the full presentation for each.
Select presentations from the Eczema and Psoriasis Research Incubator: Cross-Disciplinary Innovation Forum, hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the 55th Annual European Society for Dermatological Research (ESDR) Meeting, are now available. Topics include disease endotypes, atopic dermatitis-psoriasis overlap, cardiovascular risk in psoriasis, and genetic susceptibility.
In this Take Ten with IPC video, Juul van den Reek and PhD candidate Liana Barenbrug discuss sex differences in psoriasis, why these distinctions matter, what current research tells us, and which areas should be prioritized in future psoriasis research.
Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes
Errol Prens, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
IPC Councilor
PUBLICATION
Sex differences in immune responses that underlie COVID-19 disease outcomes. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, Lu P, Venkataraman A, Park A, Liu F, Meir A, Sun J, Wang EY, Casanovas-Massana A, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ; Yale IMPACT Research Team, Shaw A, Fournier JB, Odio CD, Farhadian S, Dela Cruz C, Grubaugh ND, Schulz WL, Ring AM, Ko AI, Omer SB, Iwasaki A. Nature. 2020 Dec;588(7837):315-320. doi: 10.1038/s41586-020-2700-3. Epub 2020 Aug 26. PMID: 32846427; PMCID: PMC7725931.
COMMENTARY
Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients. They discovered essential differences in immune responses during the disease course of SARS-CoV-2 infection in male versus female patients. First, they found that the levels of important pro-inflammatory innate immune chemokines and cytokines such as IL-8, IL-18 (at baseline), and CCL5 (longitudinal analysis) were higher in male patients, which correlated with more elevated non-classical monocytes (at baseline) and more severe disease. Second, they observed a more robust T cell response among female patients than male patients at baseline. Collectively, their data suggest that vaccines and therapies to elevate T cell immune response to SARS-CoV-2 might be warranted for male patients. In contrast, female patients might benefit from therapies that dampen innate immune activation early during disease. The immune landscape in COVID-19 patients is considerably different between the sexes. They conclude that these differences may underlie heightened disease susceptibility in men.
The authors recognize an important limitation of their study: healthy healthcare workers who served as controls were not matched to patients based on age, BMI, or underlying risk factors. Despite their corrections for those confounders in their statistical analyses, residual confounding is not ruled out due to underlying risk factors not available for the healthcare workers’ controls. The limited sample size of this study is an explicit limitation.
Categories
Recent Posts
FDA Labeling Now Aligns with the IPC and NPF Joint Position Statement on Tuberculosis Testing
Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?
Remembering Dr. Craig Leonardi
Also Read
Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?
IPC Councilor José-Manuel Carrascosa Carrillo, MD, PhD, on the BeNeBio trial and whether dose reduction fits an era focused on disease modification.
Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
Skin-Derived Myeloid Precursors and Joint-Resident Fibroblasts Spread Psoriatic Disease from Skin to Joints
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
Subscribe to the IPC Newsletter